Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Preference for Subcutaneous vs Intravenous Pembrolizumab in Multiple Tumor Types
NCT06099782Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of berahyaluronidase alfa + pembrolizumab in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and melanoma (2 arms), sponsored by Merck & Co. Primary endpoint: Percentage of Participants Who Prefer Pembrolizumab Plus Berahyaluronidase Alfa Subcutaneous (SC) As Assessed By Patient Preference Questionnaire (PPQ) Question 1 at Day 106. Started Dec 2023; status: active, not recruiting.
02
Drugs
berahyaluronidase alfa + pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)melanoma
Beyond the preview
Go deeper on NCT06099782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099782.